What are the side effects of Dupixent?

This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get. You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems . For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme

Does Dupixent interact with other medications?

• Taking a live vaccine such as measles-mumps-rubella (MMR), chicken pox or influenza vaccine is not advised during the treatment with dupilumab. • Drugs of a narrow therapeutic index such as warfarin or cyclosporine should be cautiously used along with dupilumab by closely monitoring of the drug concentration or adverse effects so that the dose can be modified. • Prescription or over-the-counter drugs or herbal supplements should be taken along with dupilumab only after the approval of the p

Can Dupixent be used during pregnancy?

( AHT ) For the active ingredient dupilumab You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.

What precautions should be taken with Dupixent?

• Patients should be advised to report to the emergency center if any allergic reactions such as urticaria or serum sickness occur. In such cases, the treatment should be discontinued and the subjects should be treated appropriately. • Patients with asthma should not stop or adjust the treatment schedule of asthma while on dupilumab without consulting the treating physician. • Eye disorders such as conjunctivitis and keratitis frequently occur and patients should be intimated to report about

What ATC class does Dupixent belong to?

Dupixent: ATC D11AH05. ATC is the WHO Anatomical Therapeutic Chemical classification — it groups drugs by organ system and pharmacological mechanism.

Dupixent

Preparing your business dashboard

Lining up the pixels…

Loading the latest data0%

This information is for educational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional.

Dupixent — Description, Dosage, Side Effects | PillsCard

( ARTG ) Dupixent is indicated for the following type 2 inflammatory diseases: Atopic Dermatitis, Adults and adolescents, Dupixent is indicated for the treatment of moderate to severe atopic dermatitis in patients aged 12 years and older who are candidates for chronic systemic therapy. Dupixent is not intended for episodic use. Children 6 months to 11 years of age, Dupixent is indicated for the treatment of severe atopic dermatitis in patients aged 6 months to 11 years old who are candidates for chronic systemic therapy. Dupixent is not intended for episodic use. Prurigo Nodularis,Dupixent is indicated for the treatment of moderate-to-severe prurigo nodularis (PN) in adults who are candidates for systemic therapy. Asthma, Dupixent is indicated as add on maintenance treatment in patients aged 6 years and older with moderate to severe asthma with type 2 inflammation (elevated eosinophils or elevated fractional exhaled nitric oxide [FeNO]) that is inadequately controlled despite therapy with other medicinal products for maintenance treatment (see Section 5.1 Pharmacodynamic Properties Clinical Trials). Chronic rhinosinusitis with nasal polyposis (CRSwNP) Dupixent is indicated as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP). Chronic obstructive pulmonary disease, Dupixent is indicated in adults as add-on maintenance treatment for uncontrolled chronic obstructive pulmonary disease (COPD) characterised by raised blood eosinophils on a stable combination of an inhaled corticosteroid (ICS), a long-acting beta2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA), or on a combination of a LABA and a LAMA if ICS is not appropriate. (see Section 5.1 Clinical Trials).Dupixent is indicated for the following type 2 inflammatory diseases:,Atopic Dermatitis,Adults and adolescents,Dupixent is indicated for the treatment of moderate to severe atopic dermatitis in patients aged 12 years and older who are candidates for chronic systemic therapy. Dupixent is not intended for episodic use.,Children 6 months to 11 years of age,Dupixent is indicated for the treatment of severe atopic dermatitis in patients aged 6 months to 11 years old who are candidates for chronic systemic therapy. Dupixent is not intended for episodic use.,Asthma,Dupixent is indicated as add on maintenance treatment in patients aged 6 years and older with moderate to severe asthma with type 2 inflammation (elevated eosinophils or elevated FeNO) that is inadequately controlled despite therapy with other medicinal products for maintenance treatment (see Section 5.1 Pharmacodynamic Properties Clinical Trials).,Chronic rhinosinusitis with nasal polyposis (CRSwNP),Dupixent is indicated as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP).

Dupixent

User Reviews